Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TK-042 Phase III Double-blind Study in Pediatric Chronic Urticaria
jRCT2031240403Phase 3Active, not recruiting
- Sponsor
- Teikoku Seiyaku Co., Ltd.
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic urticaria (CU) comparing TK-042 with Placebo (2 arms). Primary endpoint: Change from baseline in UAS7. Started Dec 2024; status: active, not recruiting.
02
Drugs
donepezil
03
Conditions
chronic urticaria (CU)
Beyond the preview
Go deeper on jRCT2031240403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240403.